Ford CE - Search Results

1

ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.

Ma SS, Srivastava S, Llamosas E, Hawkins NJ, Hesson LB, Ward RL, Ford CE. Ma SS, et al. Among authors: ford ce. BMC Cancer. 2016 Jul 20;16:508. doi: 10.1186/s12885-016-2576-7. BMC Cancer. 2016. PMID: 27440078 Free PMC article.

2

The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis.

Ford CE, Qian Ma SS, Quadir A, Ward RL. Ford CE, et al. Int J Cancer. 2013 Aug 15;133(4):779-87. doi: 10.1002/ijc.27984. Epub 2013 Jan 10. Int J Cancer. 2013. PMID: 23233346 Review.

3

The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.

Ford CE, Jary E, Ma SS, Nixdorf S, Heinzelmann-Schwarz VA, Ward RL. Ford CE, et al. PLoS One. 2013;8(1):e54362. doi: 10.1371/journal.pone.0054362. Epub 2013 Jan 11. PLoS One. 2013. PMID: 23326605 Free PMC article.

4

The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.

Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE. Loh YN, et al. Among authors: ford ce. BMC Cancer. 2013 Apr 2;13:174. doi: 10.1186/1471-2407-13-174. BMC Cancer. 2013. PMID: 23547709 Free PMC article.

5

The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Ford CE, Punnia-Moorthy G, Henry CE, Llamosas E, Nixdorf S, Olivier J, Caduff R, Ward RL, Heinzelmann-Schwarz V. Ford CE, et al. Gynecol Oncol. 2014 Aug;134(2):338-45. doi: 10.1016/j.ygyno.2014.06.004. Epub 2014 Jun 10. Gynecol Oncol. 2014. PMID: 24924122

6

Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling.

Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE. Henry C, et al. Among authors: ford ce. J Cancer Res Clin Oncol. 2015 Feb;141(2):243-54. doi: 10.1007/s00432-014-1824-y. Epub 2014 Sep 11. J Cancer Res Clin Oncol. 2015. PMID: 25209439

7

Wnt signalling in gynaecological cancers: A future target for personalised medicine?

Ford CE, Henry C, Llamosas E, Djordjevic A, Hacker N. Ford CE, et al. Gynecol Oncol. 2016 Feb;140(2):345-51. doi: 10.1016/j.ygyno.2015.09.085. Epub 2015 Sep 30. Gynecol Oncol. 2016. PMID: 26432042 Review.

8

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, Heinzelmann-Schwarz V, Ford C. Henry C, et al. Oncotarget. 2015 Nov 24;6(37):40310-26. doi: 10.18632/oncotarget.5643. Oncotarget. 2015. PMID: 26515598 Free PMC article.

9

Human Cytomegalovirus Modulates Expression of Noncanonical Wnt Receptor ROR2 To Alter Trophoblast Migration.

van Zuylen WJ, Ford CE, Wong DD, Rawlinson WD. van Zuylen WJ, et al. Among authors: ford ce. J Virol. 2015 Nov 11;90(2):1108-15. doi: 10.1128/JVI.02588-15. Print 2016 Jan 15. J Virol. 2015. PMID: 26559837 Free PMC article.

10

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.

Henry CE, Llamosas E, Djordjevic A, Hacker NF, Ford CE. Henry CE, et al. Among authors: ford ce. Oncogenesis. 2016 May 30;5(5):e226. doi: 10.1038/oncsis.2016.32. Oncogenesis. 2016. PMID: 27239958 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

281 results

Search Page

Filters